Best Clinical Genomics Companies in France
The 39 best Clinical Genomics companies in France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Vivet Therapeutics.
- Mordor Intelligence
- ResearchAndMarkets.com
Ranked: Best Clinical Genomics companies in France
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Vivet Therapeutics Developer of gene therapies for inherited metabolic diseases | $91M | 31 mo ago | 30 | Jean-Philippe Combal Co-Founder & Chief Executive Officer | Series B | 34 patents Patents concentrated in chemistry & materials | — |
| 2 | GenSight Biologics Developer of viral vector-based gene therapies for retinal neurodegenerative diseases 55AI top 15%Product top 19%Funding top 20%Patents top 33% All 11 signals ▾AItop 15% Producttop 19% Fundingtop 20% Patentstop 33% Moattop 38% Innovationtop 43% Globaltop 47% Growthbottom 47% Marketbottom 41% Newsbottom 33% Techbottom 31% AI: Holds AI/ML patents (G06N-family CPC) Product: 3 distinct product lines · Company stage: Public rank vs industry peers · Fliar Intelligence Index 55/100 | $77M | 5 mo ago | 23 | — | Public | 89 patents Optogenetic gene‑therapy vectors and precision light‑delivery devices for retinal treatments | — |
| 3 | HalioDx Developer of diagnostic product for colon cancer | $31M | 92 mo ago | 240 | — | Acqui-Hired | — | — |
| 4 | Metafora Biosystems Provider of diagnostic tests and reagents for research | $23M | 44 mo ago | 32 | Luc Dauriol Co-Founder & Chairman | Funding Raised | 37 patents Diagnostic biomarkers (GLUT1, ASCT1) and single‑cell analysis tools for hematology | — |
| 5 | IntegraGen Develops molecular diagnostic tests and genomic services. | $15M | 169 mo ago | 63 | Bernard Courtieu Chief Executive Officer | Public | 196 patents Predictive biomarkers and in‑vitro diagnostic kits for EGFR inhibitor response in cancer | — |
| 6 | Rarecells Developer of noninvasive tests for earlier cancer diagnoses | $13M | 56 mo ago | 22 | — | Series A | 20 patents Rare cell isolation, filtration, and liquid biopsy biomarker analysis for cancer diagnostics | 1 partnership |
| 7 | TcLand Expression Developer of diagnostic solutions for immune-mediated disorders and transplant patients | $11M | 92 mo ago | 11 | Huseyin Firat President & CEO | Acqui-Hired | — | — |
| 8 | PathoQuest Provider of next-generation sequencing for microbiology testing | $10M | 57 mo ago | 48 | — | Acquired | 68 patents Microbial viability assays and anellovirus quantification for clinical immune-status diagnostics | — |
| 9 | Genomic Vision Nanotechnology for single DNA analysis for cancer and acute disease molecular diagnostics | $9M | 136 mo ago | 37 | Aaron Bensimon Founder & CEO | Public | 108 patents Detection of viral DNA integration and telomere profiling for disease diagnostics | — |
| 10 | OncoDiag Developer of non-invasive cancer diagnostic solutions | $4M | 65 mo ago | 5 | Claude Hennion Co-Founder & President & CEO | Series A | 12 patents Molecular diagnostic assays for cancer, especially bladder cancer detection and monitoring | — |
| 11 | ImmunID Molecular diagnostics using immune profiling | $3M | 206 mo ago | — | Nicolas Pasqual Co-Founder & CSO | Deadpooled | 21 patents Immune repertoire sequencing for predictive diagnostics and therapy selection in oncology | — |
| 12 | LXRepair Provider of multiplexed assays for determination of the enzymatic status of cellular DNA repair | $3M | 88 mo ago | 7 | Sylvie Sauvaigo Founder & CEO | Seed | 7 patents DNA repair profiling assays for tumor cells and radiation toxicity prediction | — |
| 13 | Epigene Labs Developer of drugs through precision oncology | $3M | 49 mo ago | 25 | Akpeli Nordor Co-Founder | Seed | — | — |
| 14 | BforCure Developer of a PCR device for pathogen detection | $2M | 38 mo ago | 55 | — | Seed | 34 patents Patents concentrated in transport & manufacturing processes | — |
| 15 | En Carta Developer of molecular diagnostic tests for infectious diseases | $2M | 27 mo ago | 3 | Margot Karlikow Co-Founder | Seed | — | — |
| 16 | Acobiom Developer of diagnostics for personalized medicine applications and provided omics services | $1M | 67 mo ago | 7 | David Piquemal Co-Founder & CSO | Early Stage | 26 patents Prognostic biomarkers and survival prediction methods for pancreatic cancer patients | — |
| 17 | Vaiomer Provider of microbiome-based biomarker identification services | $555K | 92 mo ago | 11 | Rémy Burcelin Co-founder & CSO | Funding Raised | 28 patents Therapeutic polydextrose formulations and factor Xa inhibitors for metabolic diseases; microbiome‑based hepatic fibrosis diagnosti | — |
| 18 | Oncomedics Provider of a diagnostic test for the personalization of cancer treatment | $508K | 194 mo ago | — | Christophe Lautrette Founder & CEO | Seed | 11 patents Gastrointestinal sample decontamination and culture; cellular counting and aggressiveness assays for drug and cancer research. | — |
| 19 | NeoNeuro Provider of aptamer-based molecular diagnostics for Alzheimer's Disease | $363K | 72 mo ago | — | Gregory Penner Founder & President | Seed | 6 patents Aptamer-based biomarker detection for early-stage Alzheimer's disease diagnostics | — |
| 20 | Anova Plus Developd diagnostic and decision support tools for agro-industry | $223K | 80 mo ago | — | Marc Masson Founder | Deadpooled | 11 patents Field diagnostic assays for multi‑resistant fungal pathogens in cereals and human/animal health | — |
| 21 | Sebia Developer of electrophoresis-based in vitro diagnostics products | — | 44 mo ago | 87 | — | Acquired | 106 patents Patents concentrated in computing, sensing & instrumentation | — |
Top 12 Clinical Genomics companies in France
#1
Public · Paris, Ile de France · founded 2011 · 23 employees$76.6Mraised▾
Developer of viral vector-based gene therapies for retinal neurodegenerative diseases. The company develops innovative approaches to prevent retinal degeneration in selected pathological conditions, to restore vision in patients suffering from very low vision or blindness. Its lead product candidates include GS010, an AAV2 containing the human wild-type ND4 gene for the treatment of Leber Hereditary Optic Neuropathy associated with a mutation in the ND4 gene, and GS030 which comprises a gene encoding a photoactivatable channelrhodopsin for the treatment of retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration.
- Mar 2026Post IPO$2M
- Dec 2025Post IPO$3.4M
- Nov 2025Post IPO$2.3M
- Oct 2025Post IPO$4.3M
#2
Series B · Paris, Ile de France · founded 2016 · 30 employees$90.6Mraised▾
Developer of gene therapies for inherited metabolic diseases. It offers a lead gene therapy program, VTX801, targeting Wilson disease, a rare autosomal recessive genetic disorder caused by a defective gene in liver cells encoding the ATP7B protein, which can lead to organ damage, neurologic symptoms, and potentially death. The company uses a synthetic adeno-associated virus (AAV-Anc80) to introduce therapeutic genes to hepatocytes. The company is also working on progressive familial intrahepatic cholestasis types 2 and 3, and citrullinemia type I.
- Feb 2024Grant (prize money)$5.3M
- Mar 2019Series B$51.1M
- Mar 2017Series A$39.5M
#3
Funding Raised · Paris, Ile de France · founded 2011 · 32 employees$22.7Mraised▾
Metafora biosystems offers diagnostic tests and research reagents (IVD platform for drug discovery, development). They have developed few probes called RBDs which attaches to the transporters to analyze their quantity. Using the technology they have developed METAglut1 blood test to diagnose the GLUT1 deficiency syndrome (GLUT1 DS) which happens because of impairment of the major glucose transporter 1. It has an ability to target nutrient transporters at the cell surface.
- Jan 2023Grant (prize money)$2.7M
- Oct 2022Grant (prize money)$8.5M
- Jun 2020Grant (prize money)$3.6M
- Jun 2018Grant (prize money)$3.8M
#4
Seed · Paris, Ile de France · founded 2020 · 3 employees$1.6Mraised▾
Developer of molecular diagnostic tests for infectious diseases. It offers PCR-based diagnostic assays that detect attomolar concentrations of pathogens in samples like saliva, nose swabs or interstitial fluid. It offers diagnostics kit for detection of the bacterial carrier of Lyme disease, SARS-CoV-2, Zika and Chikungunya Virus.
- May 2024Seed$1.6M
#5
Acqui-Hired · Marseille, Provence Alpes Cote d Azur · founded 2015 · 240 employees$31.3Mraised▾
Developer of diagnostic product for colon cancer. The company offers HalioDx assays to determine the degree of severity of the patient’s disease and to predict response to treatment, and the molecular class of its tumor. It develops a unique line of immunologic scoring tests used in oncology which include Immunoscore for colon cancer and non-small cell lung cancer.
- Jan 2019Grant (prize money)—
- Jan 2018Series B$22.7M
- Jan 2018Grant (prize money)$501.7K
- Mar 2015Series A$8.7M
#6
Series A · Paris, Ile de France · founded 2009 · 22 employees$13Mraised▾
Developer of noninvasive tests for earlier cancer diagnoses. The company's ISET technology is able to extract a single Circulating Tumor Cell (CTC) from blood keeping CTCs intact and ready for morpho-molecular analyses.
- Dec 2021Series A$5M
#7
Acquired · Paris, Ile de France · founded 2010 · 48 employees$10Mraised▾
Provider of next-generation sequencing for microbiology testing The company has technology that combines sample preparation technology and cloud-based bioinformatics with pathogen genome sequence database and automated analysis. It helps in quality control testing of biologicals and diagnosis of infections.
- Nov 2021Series B—
- Sep 2019Series B$5M
- Sep 2019Venture Debt$3.8M
- Jul 2013Series B$5M
#8
Seed · Montreuil, Ile de France · founded 2018 · 55 employees$2.3Mraised▾
Developer of a PCR device for pathogen detection. The company has developed FASTGENE which is a point-of-care microfluidic-based temperature control device that uses real-time PCR technology for genetic material analysis and identification of pathogenic organisms. The other products are LYMIX, a reusable pretreatment cartridge, and ORTHOLIGO, proprietary software to design PCR reagents.
- Jun 2023Grant (prize money)$227.7K
- Dec 2021Grant (prize money)$223.3K
- Oct 2021Seed$2.3M
- May 2020Grant (prize money)$214.7K
#9
Public · Evry Courcouronnes, Ile de France · founded 2000 · 63 employees$14.5Mraised▾
IntegraGen develops molecular diagnostic tests and genomic services, specifically for autism and oncology. It has recently reviewed the results of the latest clinical study exploring the predictivity of miR-31-3p on the efficacy of anti-EGFR therapy in all-RAS wild-type metastatic colorectal cancer patients. It is also developing a molecular test based on the biomarker hsa-miR-31-3p, a microRNA whose expression has been correlated with the effect of EGFR TKIs (epidermal growth factor receptor tyrosine kinase inhibitors) in patients with advanced non-small cell lung cancer (NSCLC).It also developed the ARISK test to identify the risk of autism spectrum disorder (ASD) in children who have signs of developmental delay.
- Jul 2012PE$2.4M
- Nov 2006PE$2.5M
- Nov 2005Series B$9.6M
#10
Acqui-Hired · Saint Louis, Grand Est · founded 2007 · 11 employees$11.2Mraised▾
Developer of diagnostic solutions for immune-mediated disorders and transplant patients. The company specializes in the development of companion diagnostics and partners with biopharma companies for the same. Its proprietary database TcLand Atlas uses intelligent data mining and bioinformatics on pan-genomic data for analysis. Currently, TcLand is developing a multigene assay to identify patient response to infliximab and MTX combination therapy for rheumatoid arthritis. The other main product under development is a gene expression assay to identify patients who have undergone a liver transplant, and are stable enough to be with be withdrawn from immunosuppressive medication.
- Dec 2018Grant (prize money)$5.7M
- Jul 2015Grant (prize money)$5.5M
#11
Seed · Paris, Ile de France · founded 2018 · 25 employees$2.6Mraised▾
Epigene Labs is focusing on genomics-driven drug design for precision oncology. The precision oncology platform uses AI technology to analyze the genomic data to identify, design and develop therapeutics for treating cancer.
- Aug 2022Grant (prize money)$2.6M
- Oct 2021Grant (prize money)$58K
- Nov 2019Seed—
#12
Public · Bagneux, Ile de France · founded 2004 · 37 employees$8.7Mraised▾
Genomic Vision develops diagnostic and drug discovery solutions based on its nanotechnology for DNA analysis in the areas of cancer and acute diseases. These diagnostic tests and drug discovery tools operate where genome dynamics and human disease intersect. Genomic Vision uses a technique, Molecular Combing Technology, for the direct visualization of single DNA molecules to detect quantitative and qualitative changes in the genome landscape and establish their contribution to pathology. GV's initial focus is towards early cancer detection and drug therapy monitoring. The company possesses a capability for discovering genomic biomarkers implicated in the predisposition and development of many forms of cancer and in following and analyzing DNA replication during cell division. This provides an approach for evaluating the efficacy of new drugs on the cell cycle.
- May 2015Grant (prize money)$755.4K
- Jul 2008Series B$6.3M
- Dec 2005Series A$2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Clinical Genomics coverage by sub-theme.
Regulatory-risk over time flat
Funding & growth over time
funding rising · growth rising
How research on Diagnostics is moving in France
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,113 France-affiliated papers.
- Inserm246
- Centre National de la Recherche Scientifique172
- Assistance Publique – Hôpitaux de Paris104
- Institut Gustave Roussy75
- Institut de Recherche pour le Développement63
- Liquid biopsy11→30
- Cancer5→13
- Biomarker2→8
- Circulating tumor cell4→9
- Breast cancer2→7
- Liquid biopsy31→69
- Biopsy9→32
- Biomarker5→23
- Internal medicine9→27
- Point-of-care testing27→41
- Point-of-care testing13→25
- Liquid biopsy18→28
- Biopsy5→15
- Diagnostic test7→14
- Intensive care medicine2→9
Where diagnostics is researched across France
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing diagnostics patents in France
France diagnostics patent filing is steady — 21 filings from 16 assignees (2016–2025), led by Arteion, Alain Rousseau TECH & Innovation, Genewave; annual filings 1→1.
- Arteion12
- Alain Rousseau TECH & Innovation7
- Genewave3
- Floating Genes3
- Podvin Jean-marie3
- Artigue MARC2
- Marcy YANN2
- Martinelli Lucio2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.